Fact CheckerSign in

NCT06315192Recruiting

Stroke Alarm Efficacy Trial

Source: ClinicalTrials.gov · Last updated 30 Jun 2026

Brief summary (registry, in English)

The aim of this study is to test the efficacy of the CE-marked wearable system Stroke Alarm to identify the onset of a stroke with unilateral arm motor deficit within 3 hours of onset. This is a multicenter, prospective observational single-arm trial with a registry-based propensity matched control population. A total of 500 patients will be included in the trial. An interim analysis will determine if the stroke onset frequency is sufficient to determine the main outcome. Should the number of stroke events differ from what is expected at interim analysis, study enrollment will continue to increase cohort size. Patients who meet the criteria for participation will, after signing consent, be included and receive the Stroke Alarm bracelets that are used for 3 months. Study data will be collected as baseline at inclusion, at follow-up 3 months after inclusion and by using national Swedish registry data after completion of the study. Patients with elevated stroke risk according assessed by presence of specific criteria associated with elevated risk caused by: 1. recent TIA with an ABCD2 score of ≥6, large artery atherosclerosis or atrial fibrillation, OR 2. recent ischemic stroke with large artery atherosclerosis or atrial fibrillation, without persisting arm motor deficit, OR 3. atrial fibrillation with an CHA2DS2-Vasc score ≥ 4 without adequate anticoagulation OR 4. recent hemorrhagic stroke with atrial fibrillation, without persisting arm motor deficit The combined efficacy goal is at least 60% sensitivity for Stroke Alarm b of stroke with unilateral arm motor deficit within 3 hours of onset (with a 95% confidence interval above 30%) and a specificity of at least 80% using a clinical stroke diagnosis as gold standard. A control population matched for calendar year, age (± 5 years), sex, healthcare region, baseline stroke severity according to the National Institutes of Health Stroke Scale (NIHSS, ± 5 points), unilateral arm motor deficit (NIHSS item 5a/5b 1-4), presence of neglect/inattention (NIHSS item 11 1-2), atrial fibrillation, cohabitation status and pre-stroke functional level twill be identified in the Swedish national stroke registry, Riksstroke, and used for comparison.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
500 (estimated)
First submitted
11 Mar 2024
Start date
5 Sept 2024
Primary completion date
31 Oct 2027
Lead sponsor
Region Skane
NCT number
NCT06315192

What you commit to

  • Study type: Interventional
  • Planned participants: 500
  • From 5 Sept 2024 to the primary completion date, 31 Oct 2027
  • 10 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Previous inclusion in this study.
  • Arm motor deficit from any previous medical condition.

Other illness

  • Does not master any of the languages available within the Stroke Alarm smartphone app in speech and writing.
  • Does not have access to a Stroke Alarm compatible smartphone.
  • Deemed unable to handle the Stroke Alarm smartphone app, or participate in planned follow-up within the framework of the study due to other diseases or circumstances.

Other

  • Unable to give informed consent to participate in the study.
  • Does not want to participate.

Who the study is looking for

  • Age 50 years or older
  • Modified Rankin scale of 0-2.
  • Diagnosed with either:
    • Recent\* transient ischemic attack (TIA, G45.9), AND:
    • ABCD2 score of ≥6, OR:
    • Atrial fibrillation OR:
    • Large artery atherosclerosis\*\*.
    • Recent\* acute ischemic stroke (I63), AND:
    • Atrial fibrillation, OR:
    • Large artery atherosclerosis\*\*. C. Atrial fibrillation/flutter (I48), AND
    • None, or reduced dose of, oral anticoagulation medication\*\*\*, AND
    • CHA2DS2-VASC score ≥4.
    • Recent\* intracerebral hemorrhage (I61.9), AND:
    • Atrial fibrillation.
  • The patient has received the required information about the study and agrees in writing to participate.
  • Smartphone user since at least 1 year.
    • Within the last 2 weeks \*\*Atherosclerosis in carotid, vertebral aortic arch or major intracerebral arteries according to CTA or ultrasound.
    • Including all oral anticoagulation medication such as Warfarin and NOACs. Patients with reduced dose of a NOAC can be included, regardless if this is within the approved label, or if reduced dose is chosen off-label for other reasons. Treatment with antiplatelet medication is permissible.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (10)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Sahlgrenska University Hospital
Coordinator of this site? Confirm its status
GothenburgSwedenRecruiting
Hässleholms sjukhus
Coordinator of this site? Confirm its status
HässleholmSwedenRecruiting
Helsingborg lasarett
Coordinator of this site? Confirm its status
HelsingborgSwedenRecruiting
Karolinska University Hospital, Huddinge
Coordinator of this site? Confirm its status
HuddingeSwedenRecruiting
Linkoping University Hospital
Coordinator of this site? Confirm its status
LinköpingSwedenRecruiting
Skåne University Hospital
Coordinator of this site? Confirm its status
LundSwedenRecruiting
Skane University Hospital Malmö
Coordinator of this site? Confirm its status
MalmöSwedenRecruiting
Södersjukhuset
Coordinator of this site? Confirm its status
StockholmSwedenRecruiting
Karolinska sjukhuset
Coordinator of this site? Confirm its status
StockholmSwedenRecruiting
Uppsala University Hospital
Coordinator of this site? Confirm its status
UppsalaSwedenRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.